Risikoadaptierte Hormontherapie des primär operablen Mammakarzinoms-Reference-Cited by-同舟云学术

Risikoadaptierte Hormontherapie des primär operablen Mammakarzinoms

Published:2006-07 Issue:7 Volume:12 Page:662-673
ISSN:0947-8965
Container-title:Der Onkologe
language:de
Short-container-title:Onkologe

Author:

Höffken K.,Sayer H. G.,Camara O.,Runnebaum I. B.,Jänicke F.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s00761-006-1075-x.pdf

Reference61 articles.

1. Berry J (2005) Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clinical Therapeutics 11: 1671–1684

2. Boccardo F, Rubagotti A, Puntoni M et al. (2005) Switching to Anastrozole versus continued Tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozol trial. J Clin Oncol 23: 5138–5147

3. Bradbury BD, Lash TL, Kaye JA et al. (2004) Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 103: 1114–1121

4. Braithwaite RS, Chlebowski RT, Lau J et al. (2003) Meta-analyse of vascular and neoplastic events associated with Tamoxifen. J Gen Intern Med 18: 937–947

5. Brufsky A, Harker G, Beck T et al. (2004) Z-FAST Study Group Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. Breast Cancer Res Treatment 88 [Suppl 1]: S233

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapie des metastasierten Mammakarzinoms;Der Onkologe;2008-04-12